+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Indication (B-Cell Malignancies, Liver Cancer, Prostate Cancer), Technology Type, End-Use - Forecast 2024-2030

  • PDF Icon

    Report

  • 199 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 5665829
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Cellular Immunotherapy Market size was estimated at USD 11.23 billion in 2023, USD 14.02 billion in 2024, and is expected to grow at a CAGR of 25.34% to reach USD 54.60 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Cellular Immunotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Cellular Immunotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Cellular Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Adicet Bio, Inc., Apac Biotech Private Limited, AstraZeneca PLC, Atara Biotherapeutics, Inc., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Celyad Oncology SA, Corning Incorporated, Dendreon Pharmaceuticals LLC, Eli Lilly and Company, F. Hoffmann-La Roche AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Glycostem Therapeutics B.V., Immatics N.V., Inovio Pharmaceuticals, Inc., Iovance Biotherapeutics, Inc., Johnson & Johnson Services, Inc., JW Therapeutics (Shanghai) Co., Ltd., Lonza Group Ltd., Merck KGaA, Novartis AG, Pfizer Inc., and Tessa Therapeutics Ltd.

Market Segmentation & Coverage

This research report categorizes the Cellular Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Type
    • CAR T-Cell Therapy
    • Dendritic Cell Therapy
    • NK Cell Therapy
    • Tumor-Infiltrating Lymphocytes Therapy
  • Indication
    • B-Cell Malignancies
    • Liver Cancer
    • Prostate Cancer
    • Renal Cell Carcinoma
  • Technology Type
    • Cytokines & Immunomodulators
    • Monoclonal Antibodies
  • End-Use
    • Cancer Institutes
    • Hospitals
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Cellular Immunotherapy Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Cellular Immunotherapy Market?
  3. What are the technology trends and regulatory frameworks in the Cellular Immunotherapy Market?
  4. What is the market share of the leading vendors in the Cellular Immunotherapy Market?
  5. Which modes and strategic moves are suitable for entering the Cellular Immunotherapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Cellular Immunotherapy Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Prevalence of cancer and advanced cell based therapies
5.1.1.2. Favorable government initiatives for cellular therapies R&D
5.1.1.3. Increasing prevalence for tumor-infiltrating lymphocyte (TIL) therapy and engineered T cell receptor (TCR) therapy
5.1.2. Restraints
5.1.2.1. High initial costs of devices and therapies
5.1.3. Opportunities
5.1.3.1. Technological advancements and new products for cellular immunotherapy
5.1.3.2. Increasing approvals of different cell-based immunotherapy drugs
5.1.4. Challenges
5.1.4.1. Product recalls and stringent regulatory approvals
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Cellular Immunotherapy Market, by Type
6.1. Introduction
6.2. CAR T-Cell Therapy
6.3. Dendritic Cell Therapy
6.4. NK Cell Therapy
6.5. Tumor-Infiltrating Lymphocytes Therapy
7. Cellular Immunotherapy Market, by Indication
7.1. Introduction
7.2. B-Cell Malignancies
7.3. Liver Cancer
7.4. Prostate Cancer
7.5. Renal Cell Carcinoma
8. Cellular Immunotherapy Market, by Technology Type
8.1. Introduction
8.2. Cytokines & Immunomodulators
8.3. Monoclonal Antibodies
9. Cellular Immunotherapy Market, by End-Use
9.1. Introduction
9.2. Cancer Institutes
9.3. Hospitals
10. Americas Cellular Immunotherapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Cellular Immunotherapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Cellular Immunotherapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player
14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Adaptimmune Therapeutics PLC
14.1.2. Adicet Bio, Inc.
14.1.3. Apac Biotech Private Limited
14.1.4. AstraZeneca PLC
14.1.5. Atara Biotherapeutics, Inc.
14.1.6. Bio-Rad Laboratories, Inc.
14.1.7. Bristol-Myers Squibb Company
14.1.8. Celyad Oncology SA
14.1.9. Corning Incorporated
14.1.10. Dendreon Pharmaceuticals LLC
14.1.11. Eli Lilly and Company
14.1.12. F. Hoffmann-La Roche AG
14.1.13. Gilead Sciences, Inc.
14.1.14. GlaxoSmithKline PLC
14.1.15. Glycostem Therapeutics B.V.
14.1.16. Immatics N.V.
14.1.17. Inovio Pharmaceuticals, Inc.
14.1.18. Iovance Biotherapeutics, Inc.
14.1.19. Johnson & Johnson Services, Inc.
14.1.20. JW Therapeutics (Shanghai) Co., Ltd.
14.1.21. Lonza Group Ltd.
14.1.22. Merck KGaA
14.1.23. Novartis AG
14.1.24. Pfizer Inc.
14.1.25. Tessa Therapeutics Ltd.
14.2. Key Product Portfolio
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing
List of Figures
FIGURE 1. CELLULAR IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. CELLULAR IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. CELLULAR IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 7. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 8. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2030 (%)
FIGURE 12. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY TECHNOLOGY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
FIGURE 14. CELLULAR IMMUNOTHERAPY MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES CELLULAR IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CELLULAR IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. CELLULAR IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. CELLULAR IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • Adaptimmune Therapeutics PLC
  • Adicet Bio, Inc.
  • Apac Biotech Private Limited
  • AstraZeneca PLC
  • Atara Biotherapeutics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Celyad Oncology SA
  • Corning Incorporated
  • Dendreon Pharmaceuticals LLC
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Glycostem Therapeutics B.V.
  • Immatics N.V.
  • Inovio Pharmaceuticals, Inc.
  • Iovance Biotherapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • JW Therapeutics (Shanghai) Co., Ltd.
  • Lonza Group Ltd.
  • Merck KGaA
  • Novartis AG
  • Pfizer Inc.
  • Tessa Therapeutics Ltd.

Methodology

Loading
LOADING...

Table Information